Hepatocarcinoma induces a tumor necrosis factor-dependent Kupffer cell death pathway that favors its proliferation upon partial hepatectomy by Hastir, Jean-Francois et al.
ORIGINAL RESEARCH
published: 16 October 2020
doi: 10.3389/fonc.2020.547013
Frontiers in Oncology | www.frontiersin.org 1 October 2020 | Volume 10 | Article 547013
Edited by:
Prasanna K. Santhekadur,




Oslo University Hospital, Norway
Kiran Kumar Mudnakudu N,






This article was submitted to
Gastrointestinal Cancers,
a section of the journal
Frontiers in Oncology
Received: 27 April 2020
Accepted: 31 August 2020
Published: 16 October 2020
Citation:
Hastir J-F, Delbauve S, Larbanoix L,
Germanova D, Goyvaerts C, Allard J,
Laurent S, Breckpot K, Beschin A,
Guilliams M and Flamand V (2020)
Hepatocarcinoma Induces a Tumor
Necrosis Factor-Dependent Kupffer





Hepatocarcinoma Induces a Tumor
Necrosis Factor-Dependent Kupffer
Cell Death Pathway That Favors Its
Proliferation Upon Partial
Hepatectomy
Jean-François Hastir 1, Sandrine Delbauve 1, Lionel Larbanoix 2, Desislava Germanova 1,
Cleo Goyvaerts 3, Justine Allard 4, Sophie Laurent 2, Karine Breckpot 3, Alain Beschin 5,6,
Martin Guilliams 7,8 and Véronique Flamand 1*
1 Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium, 2Center for Microscopy and Molecular
Imaging, Université de Mons, Brussels, Belgium, 3 Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel,
Brussels, Belgium, 4Diapath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles, Brussels, Belgium,
5 Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium, 6Myeloid Cell Immunology
Laboratory, Vrije Universiteit Brussel, Brussels, Belgium, 7 Laboratory of Myeloid Cell Ontogeny and Functional Specialization,
VIB Center for Inflammation Research, Ghent, Belgium, 8Department of Biomedical Molecular Biology, Ghent University,
Ghent, Belgium
Partial hepatectomy (PH) is the main treatment for early-stage hepatocellular carcinoma
(HCC). Yet, a significant number of patients undergo recursion of the disease that could
be linked to the fate of innate immune cells during the liver regeneration process. In this
study, using a murine model, we investigated the impact of PH on HCC development
by bioluminescence imaging and flow cytometry. While non-resected mice were able to
control and reject orthotopic implanted Hepa1-6 hepatocarcinoma cells, resected liver
underwent an increased tumoral proliferation. This phenomenon was associated with a
PH-induced reduction in the number of liver-resident macrophages, i.e., Kupffer cells
(KC). Using a conditional ablation model, KC were proved to participate in Hepa1-6
rejection. We demonstrated that in the absence of Hepa1-6, PH-induced KC number
reduction was dependent on tumor necrosis factor-alpha (TNF-α), receptor-interacting
protein kinase (RIPK) 3, and caspase-8 activation, whereas interleukin (IL)-6 acted as
a KC pro-survival signal. In mice with previous Hepa1-6 encounter, the KC reduction
switched toward a TNF-α-RIPK3–caspase-1 activation. Moreover, KC disappearance
associated with caspase-1 activity induced the recruitment of monocyte-derived cells
that are beneficial for tumor growth, while caspase-8-dependent reduction did not. In
conclusion, our study highlights the importance of the TNF-α-dependent death pathway
induced in liver macrophages following partial hepatectomy in regulating the antitumoral
immune responses.
Keywords: Kupffer cells, hepatocellular carcinoma, liver regeneration, partial hepatectomy, cell death,
inflammation, tumor necrosis factor-alpha
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INTRODUCTION
Primary liver malignancy constitutes one of the most common
forms of cancers worldwide associated with a high mortality
rate (1). Hepatocellular carcinoma (HCC) accounts for up to
90% of these malignancies (2) and, therefore, constitutes a
major health issue. Partial hepatectomy (PH) is a commonly
used curative therapy for HCC (3) with good results at early
stage (4) and can even lead to better results than transcatheter
arterial chemoembolization within patients carefully selected
beyond the traditional Milan criteria (5). While hepatic
resection is considered as a treatment of choice, a significant
number of patients undergo recursion of the disease (6, 7).
Recurrence can be either due to the formation of de novo
tumoral site or to the presence of an ignored cryptic tumoral
site not removed during surgery. Relapse constitutes a bad
prognostic for the patient and the available therapeutic options
might get limited depending on the anatomical location of
the tumor, actual liver functions, and general status of the
patient. Therefore, the development of strategies aimed at
reducing the risk of recursion is a paramount element of
the surgery-based approach. Following PH, liver regeneration
(compensatory hypertrophy and hyperplasia without restoration
of the original anatomical shape) occurs, aiming at re-
establishing the numerous physiological functions of the organ.
Various signaling molecules and pathways are activated during
liver regeneration (including mitogen-activated protein kinases,
phosphoinositide 3-kinases, insulin-like growth factor, and
hepatocyte growth factor pathways) and participate in the
process (8, 9). Yet, major alterations of these pathways are linked
with the development and progression of liver cancers (10–
12). Immune cells play a key role in driving and participating
in the activation of the complex process leading to the
compensatory hyperplasia of hepatocytes. Most of the studies on
liver regeneration have focused on deciphering the mechanisms
leading to hepatocyte proliferation in the absence of pathology.
Therefore, the impact that PH has on immune cells and how
it affects tumor recurrence are still not fully understood. In a
normal context, Kupffer cells (KC) drive the early response to
liver partial ablation by producing tumor necrosis factor-alpha
(TNF-α) and interleukin (IL)-6 that in turn stimulate hepatocyte
proliferation through activation of nuclear factor kappa B (NF-
κB) and signal transducer and activator of transcription 3
(STAT3) pathway, respectively (13–16). Both of these cytokines
are associated with tumor aggressiveness and metastasis (10,
11). Phosphorylated STAT3 (i.e., activated) has been found in
a majority of human HCC, and this activation was associated
with tumor aggressiveness and poor prognosis (17). As for
NF-κB, its inhibition in different mouse models of HCC was
associated with limited tumor development (18). It is therefore
expected that tumor cells would be able to use TNF-α and IL-
6 signaling to their own advantage. On the other hand, NF-
κB’s ability to maintain antioxidant defenses can also contribute
to reduce liver damage (18), and in diethylnitrosamine-induced
Abbreviations:KC, Kupffer cells; TNF, Tumor necrosis factor-α; RIPK3, Receptor-
interacting protein 3 kinase; PH, partial hepatectomy; H, hepatectomy.
HCC, NF-κB participates in the maintenance of hepatocyte
survival resulting in limiting cancer development (19). TNF-α is
also a cell death inducer and a pro-inflammatory cytokine that
can activate immunity. Indeed, signaling through TNFR1 can
lead, under specific conditions, to the formation of a protein
complex containing RIPK1 and RIPK3, which can either lead
to the phosphorylation of mixed lineage kinase-like (MLKL)
and the induction of necroptosis or the activation of caspase-8
and subsequent induction of apoptosis (20). Finally, aggression
of the liver can lead to monocyte and monocyte-derived cell
recruitment. This is notably the case in other liver injury
models such as acetaminophen-induced liver fibrosis model
where monocyte-derived cells with a different phenotype than
KC (referred here as Ly6Clow macrophages) can be found
and participate in the remodeling of the organ (21). Such
population’s recruitment following PH and impact on the
recurrence phenomenon is also poorly described.
In the present study, we used an in vivo mouse model
of HCC and PH combined with bioluminescence imaging
to study the impact of PH on primary Hepa1-6 HCC
development. We demonstrated the protective role of
KC in this setup using conditional ablation and further
analyzed the in vivo mechanisms modifying the innate




Eight- to 12-week-old male C57BL/6 mice were used (ENVIGO,
Zeist, Netherlands). IL-6 KO and CCR2 KO mice were
purchased from Jackson Laboratory (Bar Harbor, ME). RIPK3
KO mice were provided by Peter Vandenabeele (Inflammation
Research Center, VIB, Ghent, Belgium). Myeloid TNF KO
mice (TNFM−KO mice; TNFflox/flox LysMcre/cre mice)
were provided by Sergei Nedospasov (Engelhardt Institute
of Molecular Biology, Russian Academy of Sciences and
Lomonosov Moscow State University, Moscow, Russia) and
KC-DTR mice were mated in our specific pathogen-free
animal facility (Gosselies, Belgium). All animals received
humane care according to the criteria outlined in the “Guide
for the Care and Use of Laboratory Animals” prepared by
the National Academy of Sciences (NIH publication 86-23
revised 1985).
Hepa1-6 and Hepa1-6-Fluc Cell Lines
Mycoplasma-free Hepa1-6 cells (ATCC) and Hepa1-6-Fluc
cells generated through transduction with lentiviral vectors
encoding firefly luciferase (transfer plasmid pDUAL_SFFV-
Fluc_Ub-puroR) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM/Lonza, BioWhittakerTM) supplemented with
10% heat-inactivated fetal bovine serum, 2mM L-glutamine,
1mM non-essential amino acids, 100mM sodium pyruvate,
penicillin (10 U/ml)–streptomycin (10µg/ml), 10–5M 2-ME
(Lonza Research Products, Basel, Switzerland), and puromycin
(5µg/ml, Sigma-Aldrich).
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Surgical Procedure for Orthotopic Tumor
Implantation and Partial Hepatectomy
Mice were injected with Hepa1-6-Fluc cells 1 week before partial
hepatectomy (H+PH group). The control group did not undergo
surgery (H group). For flow cytometry experiments, a third group
of control mice underwent phantom operation (sham group).
Mice were then used either for bioluminescence imaging or flow
cytometry experiments. For experiments investigating partial
hepatectomy, mice underwent 40% partial hepatectomy and their
liver was collected at various time points following surgery.
Under anesthesia (xylazine 50 mg/kg and ketamine 100
mg/kg), a small midline laparotomy was performed on
prehydrated (0.9% NaCl, 200 µl) mice. For tumor inoculation,
the median lobe of the liver was exposed and injected under
the Glisson’s capsule with 106 Hepa1-6 cells suspended in 50
µl PBS. For partial hepatectomy, the left lobe of the liver was
ligated and resected. Body temperature was maintained at 36.5–
37◦C during the surgical procedures. The abdominal wall and the
skin were sutured separately. Sham-operatedmice underwent the
same procedure with 50 µl PBS injection and without ligation
and resection of the left lobe of the liver.
KC Depletion
KC-DTR mice were intraperitoneally injected with 2 or 5 ng
of diphtheria toxin (Sigma) 7 days after intrahepatic Hepa1-6-
Fluc inoculation.
Bioluminescence Imaging
In vivo follow-up was performed after tumor inoculation and
carried over the 4 weeks following surgery or phantom operation.
Mice were anesthetized with 4% of isoflurane vaporized in 2
L/min O2 and then maintained with 2% isoflurane in 0.3 L/min
O2 per mouse. Before imaging, mice were shaved to decrease
the light absorption and scattering of animal fur. Each animal
received s.c. 150 mg/kg body weight of a 20-mg/ml solution
of D-luciferin in a 20-mg/ml solution in NaCl 0.9% (VivoGlo,
Promega). Mice were imaged in a Photon Imager Optima
(Biospace Lab, France) that dynamically counted the emitted
photons for at least 25min. Image analysis was performed with
M3Vision software (Biospace Lab). ROIs were drawn on the mice
abdomen in the liver area and signal intensities were quantified
individually for a time lapse of 5min corresponding to the
maximum signal intensity plateau.
Flow Cytometry
Livers were collected at various time points following resection or
phantom operation (24 h, 36 h, 2 days, or 7 days). The liver lobes
were weighted and transferred into gentleMACS tubes (Miltenyi
Biotec, Leiden, Netherlands) supplemented with RPMI 1640
medium and collagenase A (type III, Worthington Biochemicals,
New Jersey, USA) and DNase I (Roche) for one round of
the m_liver_01_03 protocol of the gentleMACS dissociator
(Miltenyl Biotec). After 20min at 37◦C, tubes completed the
m_liver_02_03 protocol of the same dissociator. The obtained
suspension was diluted in FACS buffer and passed through a
sterile 100-µm filter, centrifuged (1,400 rpm, 7min at 4◦C),
and resuspended for 1min in ammonium–chloride–potassium
lysis buffer.
Caspase-8 and caspase-1 activity assays were performed
following the manufacturer’s protocol. Cells were incubated
with FAM-FLICA (Bio-Rad AbD) for 1 h before proceeding to
standard extracellular staining. Propidium iodide (2 µl) from the
same kit (Bio-Rad AbD) was used for staining 15min at room
temperature prior to standard extracellular staining.
For standard extracellular staining, cells were resuspended
and stained in the dark at 4◦C for 20min with polyclonal
unconjugated anti-Clec4F antibodies (R&D Systems). Samples
were then incubated in the dark at 4◦C for 20min with
a mix of antibodies purchased from BD Biosciences (CD45,
Ly6G, Ly6C, CD11b, CD11c), eBioscience (F4/80, Tim4),
BioLegend (PDCA1), and Invitrogen (secondary antibody for
Clec4F detection).
For intracellular staining of p-MLKL (Ser345), cells were fixed
using the Foxp3 kit from eBioscience. Cell permeabilization
and fixation were run in accordance with the manufacturer’s
protocol. After washing, cells were incubated at 4◦C for
20min in the dark with a primary p-MLKL (Ser345) (D6E3G)
antibody (Cell Signaling Technology). After a washing step, a
secondary detection antibody (anti-rabbit IgG FabAlexa Fluor R©
488 Cell Signaling Technology) was incubated with the cells
at 4◦C for 20min in the dark. For intracellular staining of
IL-6 and TNF, cells were incubated with BD GolgiPlugTM
(1 µl/ml), phorbol 12-myristate 13-acetate (5 ng/ml), and
ionomycin (500 ng/ml) for 4 h at 37◦C prior to staining of
extracellular markers. After extracellular staining, cells were fixed
using the BD Cytofix/CytopermTM Fixation/Permeabilization
Kit. Experiments were run in accordance with manufacturer’s
protocol. Cells were incubated at 4◦C for 30min in the dark
with anti-TNF, anti-IL6, or control isotype (BD Biosciences).
Samples were measured using the BD LSR FortessaTM (BD
Bioscience, Erembodegem, Belgium). The total amount of cells
passed for each sample varies from 700,000 to 1,400,000 cells.
Data were analyzed using the FlowJo V9.9.6 software (FlowJo,
Ashland, USA).
RNA Purification and Real-Time Reverse
Transcription Polymerase Chain Reaction
Liver was collected at various time points following partial
hepatectomy or phantom operation (0min, 30min, 1 h,
2 h, overnight). RNA was extracted from liver lobes using
an EZNA HP Total RNA Kit (Omega Bio-tek, Georgia,
USA). Extracted RNA samples were quantified using the
NanoDropTM spectrophotometer and stored at −20◦C before
being used for reverse transcription quantitative polymerase
chain reaction (qPCR). For the quantification of transcripts,
reverse transcription and qPCR were performed in a single step
using the TaqMan RNA Amplification (Roche Diagnostics) on a
Lightcycler 480 apparatus (Roche Diagnostics) with the following
conditions: 10min at 50◦C, 10min at 45◦C and 30 s at 95◦C, and
then 45 cycles of 5 s at 95◦C and 30 s at 60◦C. For the granulocyte
macrophage-colony stimulating factor (GM-CSF) gene, RNA
was reverse-transcribed with the transcriptor High fidelity cDNA
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synthesis (Roche Diagnostics). cDNA was amplified using SYBR
green. For individual samples, relative RNA levels (2–11Ct)
were determined by comparing a) the cycle thresholds (Ct)
for the gene of interest and calibrator gene (1Ct), Hprt, and
b) 2–1Ct values for the experimental group vs. the reference
sample (H group). The sequences of primers and probes are
presented in Table 1.
Histology
Formalin-fixed hepatic lobes of interest were embedded in
paraffin. Five-micrometer liver sections were stained with
hematoxylin/eosin (HE). Conversion of glass slides into digital
data was performed using a NanoZoomer 9200S (Hamamatsu
Photonics K.K.). Determination of tumor size was performed
on a digital slide using the NDP.view2 software (Hamamatsu
Photonics K.K.).
Statistical Analysis
Statistical comparison between experimental groups was made
using GraphPad Prism (GraphPad Software, Inc.). The nature of
the test used is described in the figure legends. P values less than
or equal to 0.05 were considered significant.
RESULTS
Partial Hepatectomy Favors the
Proliferation of Hepa1-6 Cells in the Liver
In order to evaluate the impact of PH on tumoral development,
we used a preclinical model based on the injection of a murine
hepatocellular carcinoma cell line (Hepa1-6 cells) in the liver
median lobe. One week later, the experimental group of mice
underwent PH by resection of their left lobe, accounting for
40% of the total liver mass (H+PH group), and the control
group underwent phantom operation (H group) (Figure 1A).
Tumor implantation was confirmed by histological observations
in wild-type animals. We observed that PH increases the tumoral
burden as monitored by the increased median size of tumor
foci and higher global size of the tumor (Figures 1B,C). We
further quantified the impact of PH on tumoral development by
inoculating Hepa1-6 cells expressing the firefly luciferase enzyme
(Hepa1-6-Fluc cells) in the liver median lobe, which allowed for
in vivo follow-up of tumor over time. As described by Sakai
et al. (22), the tumoral development of Hepa1-6-Fluc cells in
the control group of mice was halted after a first week period
of proliferation (Figures 1D,E). Concerning the impact of PH
on tumor growth, bioluminescence signal in the PH group was
significantly increased 4 and 7 days after PH and underwent a
delayed abrogation after 21 days instead of 7 days in the H group
of mice (Figures 1D,E), indicating that tumor cell proliferation
is uncontrolled during liver regeneration, a process that in a
murine model takes about 1 week for completion [(8, 23) and
Supplementary Figure 1].
Partial Hepatectomy Modifies Innate
Immune Cell Composition in the Liver
We next sought to determine the possible causes of the
increased tumor proliferation we observed following PH. Since
the regeneration process is known to be relying on innate
immune cells and that KC are important gatekeepers of liver
physiology, we evaluated their absolute numbers and proportion
in total leukocyte population (determined by the expression of
CD45) using flow cytometry (gating strategies are described in
Figure 2A). First, we observed that the number of KC (CD45+
CD11bint F4/80+ Tim4+ Clec4F+ Ly6G− cells) progressively
increased and reached maximal value 9 days after tumor
inoculation in the H group of mice compared with the sham
group of mice (placebo treatment). A drastic decrease of KC
number was observed at day 2 post PH in the H+PH group
compared with the H group (Figure 2B). Then, both groups
had significantly lowered KC number compared with the sham
group 14 days post tumor inoculation (Figure 2B). Analysis of
the proportion of KC in CD45+ cells confirmed the reduction
observed 2 days after PH (Figure 2C). Yet, the increased absolute
number of cells observed in the H group at the same timing
did not translate to an increased proportion in CD45+ cells,
indicating that other CD45+ populations were recruited in this
experimental condition at that time. The absolute number of
monocytes (CD45+ CD11bhigh Ly6Chigh F4/80− Ly6G− cells)
also progressively increased and reached maximal value 9 days
after tumor inoculation in the H group compared with the
sham and H+PH groups of mice. As for KC on that day, this
increased absolute number did not translate to an increase in
the proportion in CD45+ cells. Two significant increases of
monocyte number were observed in the H+PH group at day
1 post PH when compared with the sham group and at day
7 post PH when compared with the H and sham groups. The
same type of observations was made in the proportion of CD45+
cells with a significant increase observed at day 1 and day 7
post PH (Figures 2B,C). Concerning the Ly6Clow macrophages
(CD45+ CD11b+ Ly6Cint Ly6G− CD11c− pDCA1−), their
number increased significantly at day 7 post PH in the H+PH
group compared with the H group of mice (Figure 2B). This
observation corroborated the one made when analyzing the
proportion of these cells in CD45+ population. Moreover, a
significantly higher proportion of Ly6Clow macrophages were
also observed as early as day 2 post PH (Figure 2C). In contrast to
KC, both numbers of monocytes and Ly6Clow macrophages were
increased compared with the sham group 7 days post PH.
Taken together, our results demonstrate that PH induced a
drop in KC number in tumor-bearing liver and an “earlier”
monocyte influx as well as another “delayed” monocyte
recruitment that correlates with a late increased number and
proportion in CD45+ cells of Ly6Clow macrophages in the organ.
KC Depletion Results in an Increased
Hepa1-6 Proliferation
The reduction of KC observed in mice undergoing PH associated
with the increased tumor proliferation raised the possibility that
they would be important agents in the antitumoral process.
Macrophages are known for their dual role during cancer
development, and while resident cells can limit its progression
in early stages, tumor-associated macrophages derived from
monocytes found at a later time point have an anti-inflammatory
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TABLE 1 | The sequences of primers and probes.
Gene Forward Reverse Probe PCR product
MCP1 CTTCTGGGCCTGCTGTTCA CCAGCCTACTCATTGGGATCA CTCGCCAGATGCAGTTAACGCCCC 127 bp
GM-CSF ACCCGCCTGAAGATATTCG AGCTGGCTGTCATGTTCAAG / 69 bp
IL6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA CAGAATTGCCATTGCACAACTCTTTTCTCA 140 bp
TNFα CAGACCCTCACACTCAGATCA CACTTGGTGGTTTGCTACGA TCGAGTGACAAGCCTGTAGCCCA 78 bp
HPRT GGACCTCTCGAAGTGTTGGAT CCAACAACAAACTTGTCTGGAA CAGGCCAGACTTTGTTGGATTTGAA 70 bp
FIGURE 1 | Proliferation of Hepa1-6 cells is increased following partial hepatectomy. (A) Experimental procedure used. Mice were injected with Hepa1-6-Fluc cells 1
week before partial hepatectomy (H+PH group). The control group did not undergo surgery (H group). (B) Liver histology visualized by HE staining. Representative
pictures of the nonresected (H) and resected (H+PH) experimental groups. (C) Quantification of tumor burden by mean size of tumor foci (left panel) and percentage
of tumor on a slide (right panel) in wild-type animals. (D) Representative image of the bioluminescence data generated until 7 days post PH. (E) Bioluminescence
signal detection over time following partial hepatectomy. Two-tailed Mann–Whitney test, *p < 0.05. Results presented as median and interquartile range (n = 7/group)
from at least three independent experiments.
“alternatively activated” (M2) phenotype. This is notably known
in humans asHCCwhere later-stage patients with poor prognosis
have increased M2 macrophages infiltrating the tumor (24).
Nevertheless, PH is a treatment reserved for early-stage patients
and it is thus expected that liver-resident KC would limit cancer
development. To evaluate the impact of the decreased KC
number on tumor growth, we mimic the effect of PH-induced
KC disappearance by using KC-DTR mice previously described
by Scott et al. (25). This strain has the unique characteristic
of being specifically depleted in the KC compartment after
diphtheria toxin (DT) injection in a dose-dependent manner
(25). We used a single 2-ng injection of DT (Figure 3A)
that does not cause side effects on the liver regeneration
post PH as evaluated by the liver to body weight ratio in
WT mice (Supplementary Figure 2A). That DT dose caused
a partial decrease of KC numbers (Supplementary Figure 2B),
which went back to pre-injection level 1 week following the
injection (Figure 3B). This recovery was associated with a
decreased number of monocytes in the organ 2 days post
DT injection. No significant modifications in the Ly6Clow
macrophage compartment could be observed at tested timing
(Figure 3B), demonstrating that our model specifically induces
modifications in the KC compartment.
Next, we observed a significantly increased proliferation of
Hepa1-6-Fluc cells during the first week following the 2-ng
DT injection, while PBS-injected mice naturally rejected the
tumor (Figures 3C,D), effectively recapitulating the previous
observations in mice undergoing liver regeneration (Figure 1).
Taken together, our results indicate that the reduction of the
absolute number of KC observed in mice undergoing liver
regeneration might, at least partially, explain the increased
tumoral proliferation observed in this condition, raising the
question on the mechanisms leading to KC disappearance.
TNF and IL-6 Influence KC Survival During
Liver Regeneration and Impact the Tumor
Proliferation
We next wanted to decipher the mechanism linking the KC
number reduction and the increased tumor growth induced upon
PH. We observed that the transcript levels of IL-6 and TNF, two
major actors of liver regeneration, were significantly increased
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FIGURE 2 | Absolute number and proportion of Kupffer cells among CD45+ cells are reduced following PH, while monocytes and Ly6Clow macrophages increase
after surgery. (A) Representative picture of the gating strategies used for the discrimination of Kupffer cells, monocytes, and Ly6Clow macrophages. (B) Kinetics of the
number of Kupffer cells, monocytes, and Ly6Clow macrophages following PH in C57BL/6 mice liver. Flow cytometry analyses were done 0, 1, 2, and 7 days following
PH (H+PH group) or phantom operation (H group). The sham group was injected with physiological serum and received placebo surgery 7 days later. *p < 0.05, **p
< 0.01, Kruskal–Wallis/one-way ANOVA followed by Dunn’s post hoc test/Bonferroni’s multiple comparison test between the H and H+PH groups/#p < 0.05, ##p
< 0.01, Kruskal–Wallis/one-way ANOVA followed by Dunn’s post hoc test/Bonferroni’s multiple comparison test between the sham and H and H+PH groups (n =
4–9/time point). Choice of the test was based on the result of the Shapiro–Wilk normality test. Results presented as median and interquartile range from at least three
independent experiments. (C) Kinetics of the proportion among leukocytes (CD45+ cells) of Kupffer cells, monocytes, and Ly6Clow macrophages following PH in
C57BL/6 mice liver. Flow cytometry analyses were done 0, 1, 2, and 7 days following PH (H+PH group) or phantom operation (H group). The sham group was
injected with physiological serum and received placebo surgery 7 days later. *p < 0.05, **p < 0.01, ***p < 0.001, Kruskal–Wallis/one-way ANOVA followed by Dunn’s
post hoc test/Bonferroni’s multiple comparison test between the H and H+PH groups/#p < 0.05, ##p < 0.01, ###p < 0.001, Kruskal–Wallis/one-way ANOVA
followed by Dunn’s post hoc test/Bonferroni’s multiple comparison test between the sham and H and H+PH groups (n = 4–9/time point). Choice of the test was
based on the result of the Shapiro–Wilk normality test. NS, not significant.
FIGURE 3 | Proliferation of Hepa1-6 cells is increased following Kupffer cell depletion. (A) Experimental procedure used. Mice were injected with Hepa1-6-Fluc cells 1
week before intraperitoneal injection of diphtheria toxin (DT 2 ng group) or PBS. (B) Kinetics of the absolute number of KC, monocytes, and Ly6Clow macrophages in
KC-DTR mice after 2-ng DT injection. *p < 0.05, **p < 0.01, Kruskal–Wallis followed by Dunn’s post hoc test. Results presented as median. (C) Representative image
of the bioluminescence data generated until 7 days post injection. (D) Bioluminescence signal detection over time following injection. Two-tailed Mann–Whitney test,
**p < 0.001. Results presented as median and interquartile range (n = 7–8/group) from at least three independent experiments.
in the partially resected liver 1 h post surgery (Figure 4A).
This increase was also observed at protein level 24 h after
surgery. Intracellular staining of IL-6 and TNF revealed a
significant increase of the median fluorescence intensity and
the proportion of CD45+ cells positively stained following PH
as compared with the control group (Figures 4B,C). We also
observed that following PH, the myeloid compartment of CD45+
cells (discriminated on the basis of CD11b expression) had a
significantly higher proportion of cells positively stained for both
cytokines than the CD11b− cells (Figure 4D).
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FIGURE 4 | IL-6 and TNF are induced following partial hepatectomy. (A) Relative expression in total liver of C57BL/6 mice of IL-6 and TNF over time following PH or
phantom sham operation. *p < 0.05, two-tailed Mann–Whitney test (n = 3–7/time point). (B) Median fluorescence intensity (MFI) of C57BL/6 CD45+ cells stained for
TNF, IL-6, or control isotype (isotype group) 24 h following partial hepatectomy (PH group) or phantom operation (sham group). *p < 0.05, Kruskal–Wallis followed by
Dunn’s post hoc test. Results presented as median and interquartile range. (C) Frequency of CD45+ cells producing TNF or IL-6 24 h following partial hepatectomy
(PH group) or phantom operation (sham group). Determination of positive gate was based on isotype control staining. Results presented as median. *p < 0.05, **p <
0.01, two-tailed Mann–Whitney test. Results presented as median. (D) Frequency of CD11b− cells and CD11b+ producing TNF or IL-6 24 h following partial
hepatectomy. Cells were firstly gated for CD45 expression. Determination of positive gate was based on isotype control staining. **p < 0.01, two-tailed Mann–Whitney
test. Results presented as median.
First, we evaluated the role of IL-6 in the outcome of KC post
PH. We observed that IL-6 KO mice displayed a faster decrease
in KC numbers 24 h following resection (Figure 5A), whereas
WT mice underwent a decrease 2 days post PH. This indicates
that IL-6 would act as a KC cytoprotective factor. Moreover,
tumoral proliferation was strongly increased in the H+PH group
of IL-6 KO mice compared with the H group 7, 14, and 21 days
post PH (Figure 5B). Of note, in this strain compared with WT
mice, both the H and H+PH groups failed at rejecting the tumor
even at day 21, strengthening the role of IL-6 as a major early
contributor to KC survival and to the liver protection against
tumor proliferation.
Next, we evaluated the role of TNF and the RIPK3 cell death-
associated signaling molecule. To do this, we ran PH experiments
in TNFflox/floxLysMCre/WT mice (TNFM−KO mice with exclusive
Tnf gene deletion in lysozyme M-expressing myeloid cells like
monocytes, neutrophils, and macrophages) and in RIPK3 KO
mice. We observed that the PH-induced KC disappearance
observed in C57BL/6 mice was abrogated in TNFM−KO mice
and in RIPK3 KO mice (Figure 5B). Interestingly, we observed
that the TNFM−KO and RIPK3 KO strains showed no increased
Hepa1-6-Fluc cell proliferation after PH (Figure 5C).
Liver Resection Induces a
RIPK3-Dependent Activation of Caspase-8
in KC
We next sought to determine the mechanism responsible for the
TNF-dependent KC reduction following PH (i.e., KC apoptosis
via caspase-8, necroptosis via phosphorylation of MLKL, or
pyroptosis via caspase-1). In assays determining the functional
ability of the protein, we detected an increased caspase-8 activity
but no increased levels of caspase-1 and p-MLKL (Ser345)
in WT mice KC following PH (Figure 6A). Neither increased
caspase-8 activation nor increased level of p-MLKL (Ser345)
was observed in RIPK3 KO KC under the same condition
(Figure 6B). Taken together, our results support the idea that
following PH, KC undergo a TNF/RIPK3-dependent apoptosis




Activation of Caspase-1 in KC Following
PH
We further evaluated the role of TNF/RIPK3 in the fate of
KC post PH in tumor-inoculated mice. While PH-induced KC
disappearance was still abrogated in H+PH TNFM−KO mouse,
we observed a sharp drop of KC in H+PH RIPK3 KO mice 2
days post PH (Figure 7A), in opposition with KC survival in
tumor-free RIPK3 KOmice after PH (Figure 5A). This suggested
that Hepa1-6 had an impact on the cell death signaling pathway.
Indeed, in contrast with KC from WT mice undergoing PH
(Figure 6A), KC from the H+PH group of WT mice were no
longer associated with an increase in caspase-8 activity nor
increased level of p-MLKL (Ser345) post PH (Figures 7B,C).
Yet, an increased fraction of KC was positively stained with
propidium iodide at the same timing (Figure 7D), indicating
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FIGURE 5 | PH-induced Kupffer cell number reduction is regulated by TNF-α and IL-6. (A) Absolute number of KC in C57BL/6, IL-6 KO, TNFM−KO, and RIPK3 KO
mice. Analyses were run at day 1 or 2 following PH. The control sham group underwent phantom operation. (B) Bioluminescence signal detection over time following
partial hepatectomy in IL-6 KO, TNFM−KO, and RIPK3 KO mice. Two-tailed Mann–Whitney test, *p < 0.05, **p < 0.01, NS: non-significant difference (n = 7–8/group).
All results presented as median and interquartile range from at least three independent experiments.
FIGURE 6 | PH induces a RIPK3-dependent apoptosis of Kupffer cells. (A, upper panel) Median fluorescence intensity (MFI) of C57BL/6 KC stained with
fluorescent-labeled inhibitor of caspase-8 36 h post PH and representative histogram of the fluorescence intensity. **p < 0.01, two-tailed Mann–Whitney test. (A,
middle panel) MFI of C57BL/6 KC stained for Ser345 phosphorylated MLKL (p-MLKL Ser345) 36 h post PH and representative histogram of the fluorescence intensity.
(A, lower panel) MFI of C57BL/6 KC stained with labeled inhibitor of caspase-1 36 h post PH and representative histogram of the fluorescence intensity. (B, upper
panel) MFI of RIPK3 KO KC stained with fluorescent-labeled inhibitor of caspase-8 36 h post PH and representative histogram of the fluorescence intensity. Results
presented median and interquartile range. (B, lower panel) MFI of RIPK3 KO KC stained for p-MLKL Ser345 36 h post PH and representative histogram of the
fluorescence intensity. All results presented as median and interquartile range from at least three independent experiments.
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FIGURE 7 | Tumor encounter switches caspase-8 activation to caspase-1 activation in KC following partial hepatectomy. (A) Kinetics of KC following PH in TNFM−KO
and RIPK3 KO mice liver. Flow cytometry analyses were done 0, 1, 2, and 7 days following PH (H+PH group) or phantom operation (H group). The sham group was
injected with physiological serum and received placebo surgery 7 days later. *p < 0.05, Kruskal–Wallis followed by Dunn’s post hoc test between the H and H+PH
groups/#p < 0.05, Kruskal–Wallis followed by Dunn’s post hoc test between the sham and other experimental groups (n = 5–9/time point). Test chosen based on the
result of the Shapiro–Wilk normality test. (B) MFI of C57BL/6 or RIPK3 KO KC from mice injected with Hepa1-6 cells and stained with fluorescent-labeled inhibitor of
caspase-8 36 h post PH or phantom operation (sham) and representative histogram of the fluorescence intensity. *p < 0.05, two-tailed Mann–Whitney test. (C) MFI of
KC of C57BL/6 from mice injected with Hepa1-6 cells, stained for p-MLKL Ser345 36 h post PH and representative histogram of the fluorescence intensity. (D)
Percentage of positive KC for propidium staining 36 h post PH and representative dot plot of the staining. **p < 0.01, two-tailed Mann–Whitney test. (E) MFI of
C57BL/6 or RIPK3 KO KC from mice injected with Hepa1-6 cells and stained with fluorescent-labeled inhibitor of caspase-1 36 h post PH and representative
histogram of the fluorescence intensity. *p < 0.05, two-tailed Mann–Whitney test. All results presented as median and interquartile range from at least three
independent experiments.
that they were undergoing cell death. We further observed that
KC from H+PH WT mice displayed an increased caspase-
1 activity, a hallmark of pyroptosis (Figure 7E). We further
linked inflammasome activation with TNF/RIPK3 signaling
by demonstrating that KC from RIPK3 KO mice were, in
contrast to WT mice, positive for caspase-8 but not for caspase-
1 activity under the same conditions (Figures 7B,E). Taken
together, our results support that tumor encounter modifies
the TNF/RIPK3-dependent induction of caspase-8 activity to
TNF/RIPK3-dependent caspase-1 activity after PH. This suggests
an effective switch from apoptosis to pyroptosis induction in KC.
KC Death Pathway Influences the
Recruitment of Ly6Clow Macrophages and
Monocytes Promoting Tumor Growth
The protection against the PH-induced tumoral proliferation
in RIPK3 KO mice remained unexplained from the previous
experiments. We noticed that in contrast to WT mice, RIPK3
KO mice and TNFM−KO mice did not display any increase
in monocytes nor Ly6Clow macrophages 7 days post PH
(Figures 8A,B). Taking into account the previously shown
correlation between the presence of monocytes and Ly6Clow
macrophages, we first demonstrated that PH induces the
expression of CCL2 (a chemoattractant for monocyte) and
GM-CSF in the early hours following PH in tumor-free
wild-type mice (Supplementary Figure 3A). We then followed
the kinetics of Ly6Clow macrophages and monocytes in PH
wild-type mice (Supplementary Figure 3B). Recruitment of
Ly6Clow macrophages in wild-type strain was especially striking
on day 2 post PH. Moreover, CCR2 KO liver had an
effective reduction of both monocytes and Ly6Clow macrophages
(Supplementary Figure 3B) with no modifications of the KC
compartment kinetics post PH.
Zigmond et al. (21) described the restorative and remodeling
aspect of similar Ly6Clow macrophages, which raised the
hypothesis that these cells might be beneficial for tumor
development. This idea was strengthened by the finding of a
strong correlation (Pearson correlation, R = 0.8909/p = 0.0011)
between the amount of Ly6Clow macrophages in the liver and
the size of the tumor assessed by histological analysis at the
same timing (Figure 8C). Moreover, the CCR2 KO strain showed
no significantly increased tumor proliferation following PH
(Figures 8D,E), and the protection observed in RIPK3 KO strain
can, at least partially, be attributed to the absence of recruitment
of these cells.
DISCUSSION
Partial hepatectomy gives a good overall survival chance
in patients carefully selected (5, 26). Yet, tumor recurrence
constitutes a major problem for this approach with complications
in nearly 70% of the cases at 5 years (7, 26). Complications can
arise notably from occulted tumor sites, a scenario that ourmodel
reproduces. Clinical and experimental studies have suggested
that liver regeneration following surgical resection facilitates
tumor growth following a surgery procedure (27–29), a concept
that our results support.
While the importance of T-cell immunity in the rejection
of the Hepa1-6 cell line was described previously (22), an
observation that we confirmed in our model (data not shown),
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FIGURE 8 | PH induces a recruitment of monocyte-derived cells favorable for tumor proliferation that correlates with the differential death pathway activated in KC.
(A, B) Absolute number of monocytes and Ly6Clow macrophages in C57BL/6, TNFM−KO, and RIPK3 KO mice injected with Hepa1-6. Flow cytometry analyses were
done 7 days following PH (H+PH group) or phantom operation (H group). The sham group was injected with physiological serum and received placebo surgery 7
days later. *p < 0.05, **p < 0.01, Kruskal–Wallis followed by Dunn’s post hoc test. (C) Pearson correlation analysis between absolute number of Ly6Clow
macrophages and size of the tumor. Absolute number of cell was determined by flow cytometry and tumor size by histological analysis (percentage of tumor on a
slide) from wild-type animals at day 7. Pearson correlation (R-value) and statistical significance (p-value) are displayed. (D) Representative image of the
bioluminescence data generated until 7 days post PH in CCR2 KO mice. (E) Bioluminescence signal detection over time following partial hepatectomy. Two-tailed
Mann–Whitney test, *p < 0.05. Results presented as median and interquartile range (n = 5/group) from at least three independent experiments. NS, not significant.
our results clearly demonstrate a role for KC, and therefore the
innate immunity component, in tumor rejection. This places KC
at the intersection between the induction of liver regeneration
and antitumoral responses.
Based on our flow cytometry observations and KC-DTR
bioluminescence experiments, we suggest that during the
early stages of tumoral development, the absence of KC
induced by PH participates in increased tumoral proliferation,
while maintenance of their number (and presumably their
inflammatory factors) allows for accelerated rejection of the
tumor cells. Interestingly, we could observe a reduction in
the amount of monocytes in KC-DTR mice 2 days following
DT injection. As already demonstrated in the KC-DTR strain,
following DT injection, monocytes are recruited and differentiate
in KC. Stellate cells and endothelial cells orchestrate this
phenomenon (30). We therefore expect the same differentiation
mechanism to be responsible for our observation.
The reduction in KC number following PH seemed to
replicate the diminution observed in bacterial and ischemia–
reperfusion injury models. In particular, the importance of KC
necroptosis induced by phagocytosis of bacteria, in generating
antimicrobial response production of CCL2 and IL-1β, has
underlined the death pathway induced in macrophages as
an element regulating inflammation (31). While our results
ruled out necroptosis as the reason for KC reduction since
no increase of phosphorylated MLKL level could be seen,
we firstly described the TNF-α/RIPK3-dependent activation of
caspase-8 occurring in KC upon PH. Presumably, activation of
the complex IIb downstream of TNFR1 mediates KC apoptosis
between days 1 and 2 following PH (Figure 8). TNF induces
IL-6 production by KC and triggers hepatocyte proliferation
via STAT3 activation during the regenerative process (8). While
our results demonstrate that IL-6 is also a crucial factor for
KC maintenance and survival in early stages of the regenerative
process as well as for tumor clearance, complex IIb formation
and subsequent apoptosis might be seen as a way to regulate KC
activity following PH and avoid oversignalization via complex I,
NF-κB activation, continuous inflammation, and damages in the
regenerating organ.
Our study also shows for the first time that the concomitant
growth of tumoral cells effectively switches caspase-8 to caspase-
1 activation in KC. While these results suggest an induction of
pyroptosis in these cells after PH, detection of cleaved Gasdermin
D (a pore-forming protein that is activated after cleavage by
caspase-1) within KC would be necessary to confirm this idea.
Nevertheless, this activation of cell death mechanisms within KC
following PH alongside the effective switch we observed and the
importance this switch has on the recruitment of monocytes and
monocyte-derived cells beneficial for the tumor had up until now
never been documented in this context. Based on our results and
published literature, we therefore propose the model presented in
Figure 9.
The switch we observed was fully dependent on TNF and
RIPK3 signaling since TNFM−KO mice did not show a reduction
in KC number and RIPK3 KO KC exhibited increased caspase-8
over caspase-1 activity. RIPK3 is able to activate NLR family pyrin
domain containing 3 (NLRP3) inflammasome independently of
MLKL presence in bone marrow-derived macrophages (32), and
a similar mechanism might be occurring in KC. In dendritic
cells, caspase-8 activity was shown to regulate RIPK3-dependent
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FIGURE 9 | Proposed model of how TNF-α and RIPK3 induce KC death following PH. Following PH, IL-6 acts on KC as a pro-survival signal. In the absence of tumor,
TNF signaling leads to the activation of complex IIb and the apoptosis of KC through activation of caspase-8 between day 1 and day 2. The presence of tumor cells
within the organ leads to a switch in the activation of cell death pathways and the RIPK3-dependent activation of caspase-1, probably through the activation of
inflammasome macromolecular complexes. This KC death was linked with a CCL2-dependent recruitment of Ly6Clow macrophages. This latter population was shown
to favor tumor development, while KC maintenance accelerated antitumoral responses. Critical elements demonstrated in the paper are described with red arrows
and fonts, while deduction from the literature is in blue.
activation of the NLRP3 inflammasome, and suppression of
caspase-8 activity favored pyroptosis induction (33). The fact
that we observed caspase-8 activity but no caspase-1 induction
in KC following PH in animals without tumor might hint
toward an analogous regulation in KC. We can only speculate
on how the switch from apoptosis to pyroptosis is made.
Inflammasome assembly and activation mechanism is still a
subject of debate especially for NLRP3. Yet, the current model
proposes two distinct signals to be necessary (34): the priming
signal being transmitted via TLRs, IL-1R, TNFR, or NOD2
and the second signal depending on Ca2+ signaling, K+ efflux,
changes in cell volume, or rupture of lysosomes or reactive
oxygen species (ROS). Tumor proliferation, the inflammation
generated against it via IL-1β secretion or liberation of DAMPs
from dying cells, which are potent TLR ligands, might be
participating in the process. Nevertheless, differential death
pathway activation in KC leads to different recruitment of
monocytes and monocyte-derived macrophages beneficial for
tumor proliferation as the data from CCR2 KO mice confirmed.
Even though the first clinical trials using carlumab (CNTO888),
a human anti-CCL2 antibody, had disappointing results (35,
36) (despite overall low toxicity), modulation of the CCL2–
CCR2 axis seems to be a promising way to alleviate the risk of
recurrence following PH.
Monocytes are known for their vascular remodeling abilities,
and in acute APAP-induced liver injury, monocyte-derived
Ly6Clow macrophages, with a similar phenotype to the cells
we observed, were shown to be important elements for the
resolution of inflammation and to have wound healing and
tissue remodeling abilities (21). Moreover, in the subcutaneous
tumor developmentmodel, monocyte-derived CD11b+ MHCII−
Ly6Cint cells infiltrating the tumor were shown to suppress T-cell
proliferation and to have important proangiogenic abilities (37).
While those models differ from ours, the close phenotype and the
same cellular origin of those cells might be giving a hint toward
their protumoral activity in our observations. Since RIPK3
KO KC died from apoptosis and no monocyte nor Ly6Clow
macrophage recruitment was observed, it is reasonable to think
that upon inflammation induced by pyroptosis of KC, circulating
monocytes are recruited and differentiate into the organ in cells
phenotypically different from KC, while a less inflammatory
cell death (apoptosis) would not lead to such recruitment and
differentiation. These observations might help in understanding
the clinical problems faced in tumor embolization protocol and
the re-revascularization of the tumor site and overall tumor
growth (38).
The dependence of KC death on TNF signaling raises the
possibility for the development of strategies aiming at enhancing
tumor rejection. The use of anti-TNF antibody treatment is
standard nowadays for rheumatoid arthritis and is also of
interest for a variety of other autoimmune disease such as
Crohn’s disease, psoriasis, ulcerative colitis, and ankylosing
spondylitis (39). Yet, this approach has not always been efficient,
as shown in multiple sclerosis (40), or even dangerous for
patients, as demonstrated in clinical trials for heart failure
(41, 42). Based on the protection against tumor proliferation
observed in TNFM−KO mice and since TNF signalization is
also associated with ischemia–reperfusion injury (another liver-
damaging reaction occurring in humans following PH due
to a surgical procedure), it seems rational to hypothesize a
potential beneficial impact of anti-TNF treatment in patients
following PH. Yet, caution should be taken when transposing
our results in humans, and choosing the right balance between
liver regeneration and tumor rejection might be complex.
This would be probably achieved by careful selection of the
timing at which the treatment would be implemented. The
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background on which tumor has developed might also be of
importance when assessing the effect of anti-TNF treatment
since HCC develops mainly in the liver with a previous
inflammatory environment due to pathogen (HBV/HCV) or
excessive alcohol consumption (alcoholic liver cirrhosis) (43).
Other than anti-TNF treatment, specific macrophage inhibitor
of pyroptosis might be just as relevant in our specific
case. In conclusion, our work highlights the necessity for a
comprehensive multidisciplinary treatment approach following
PH in order to reduce the risk of complications occurring
after surgery.
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